MedTrace Logo

Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates.

NCT07255742 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-02-02

No results posted yet for this study

Summary

The aim of the study is to

1. Evaluate the preventive value of Lactoferrin on VAP among ventilated neonates.
2. Evaluate the Primary outcome of Lactoferrin on:

Sepsis, Feeding intolerance, Vomiting, Constipation or diarrhea
3. Evaluate the effect of Lactoferrin in critically ventilated neonates on:

Incidence of VAP Duration of mechanical ventilation Duration of hospital stay

Conditions

  • Ventilator Associated Pneumonia

Interventions

DIETARY_SUPPLEMENT

Lactoferrin in prevention of VAP

oral dose separate from feeds \[at a daily dose of 100mg/day\] via orogastric tube from first day of enrollment till time of successful extubation plus standard preventive measures of VAP; these include semi recumbent position, hand washing, suctioning when needed, endotracheal tube with subglottic secretion drainage, using heat and moisture exchanger filter, oral hygiene, changing of tubes only when needed and changing of ventilator circuit every 5 days.

OTHER

Control

They will receive standard preventive VAP strategies only.

Sponsors & Collaborators

  • Dalia Mohamed Salah

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
0 Days
Max Age
90 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2025-12-01
Completion
2025-12-04

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07255742 on ClinicalTrials.gov